| Peer-Reviewed

Analysis of Drug Resistance of 157 Strains of Multidrug Resistant Mycobacterium Tuberculosis in Jilin Province

Received: 2 August 2022     Accepted: 26 August 2022     Published: 16 September 2022
Views:       Downloads:
Abstract

Objective: Through the analysis of drug resistance of 157 strains of multidrug resistant Mycobacterium tuberculosis in Jilin Province, the drug resistance spectrum of multi drug resistant Mycobacterium tuberculosis in Jilin Province was preliminarily established to provide the basis for the treatment of patients with multi drug resistant tuberculosis in the future. Methods: Anti-tuberculosis streptomycin (SM), ethambutol (EMB), of loxacin (OFX) and kanamycin (KM) were tested by L-J ratio. Results: The SM resistance rate in 157 MDR M. tuberculosis strains was 56.05%, EMB The resistance rate 38.85%, OFX The resistance rate 64.97%, KM The resistance rate 14.65%. The XDR resistance rate was 14.01%. The results of drug resistance analysis in different characteristic populations show that second-line drugs OFX and KM drug resistance rates Female patients Higher than male, and statistically significant (P < 0.05), the resistance rate of OFX relapse patients was significantly higher than that in naive patients, and was statistically significant (P < 0.05). Conclusion: The resistance rate of tuberculosis patients in Jilin Province to the first-line and second-line anti-tuberculosis drugs is at a relatively high level, and the situation of tuberculosis prevention and control is not optimistic. The management of patients should be strengthened in the prevention and treatment strategies, and the use of anti-tuberculosis drugs should be standardized, At the same time, strengthen the ability of tuberculosis laboratory to detect drug-resistant Mycobacterium tuberculosis is strengthened.

Published in International Journal of Clinical and Experimental Medical Sciences (Volume 8, Issue 5)
DOI 10.11648/j.ijcems.20220805.11
Page(s) 65-68
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Mycobacterium Tuberculosis, Multidrug Resistance, Drug Resistance Rate

References
[1] World Health Organization. Global tuberculosis report 2020 [R/OL]. (2020-10-14).
[2] Cao Lixue, Lin Yanli, Wu Xueqiong. Exhibition of rifampin resistance in M. tuberculosis. Biotech Bulletin, 2004, 15: 79-82.
[3] World Health Organization. Global tuberculosis report 2019 [R/OL]. (2019-10-17).
[4] Zhao Yanlin, Wang Lixia. Standardized operating procedures and quality assurance manual for M. tuberculosis drug sensitivity test [M]. Beijing: People's Health Press, 2013: 24-30.
[5] Zheng Rongrong, Zhang Xiangdong, Huang Chengji. Analysis of drug resistance in 875 M. tuberculosis strains [J]. Modern preventive Medicine, 2008, 35 (23): 4 697-4 698.
[6] Word Health Oraanization. Anti-tuberculos is Drug Resistance in The word, Fourth Global Report. The WHO/IUATLD Global Project on Anti-tuberculos is Drug Resistance Surveillance [J]. Geneva WHO 2008.
[7] Word Health Oraanization. Global tuberculos report 2013. Oct 2013.
[8] Ministry of Health, PRC. The National Baseline TB Drug Resistance Survey Report (2007-2008). Beijing: People's Health Publishing House, 2010.
[9] Zhang Weiyu, Yang Xiujun, Wang Bo, et al. Analysis of drug susceptibility results of 238 multidrug-resistant M. tuberculosis strains in Jilin Province [J]. Health Engineering in China, 2015, 014 (006): 540-541.
[10] Zhang Zhijian et al. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. [J]. Antimicrobial agents and chemotherapy, 2014, 58 (1): 364-9.
[11] Che Yang, Yang Tianchi, Pingguohua, et al. Epidemic of Beijing genotype of MDR-Mycobacterium tuberculosis and its relationship with quinolone resistance in Ningbo, Zhejiang Province [J]. Disease surveillance, 2017, 32 (12): 962-965.
[12] Zhao Wei, Liu Sijie, Li Kewei, et al. Analysis of the resistance of 894 M. tuberculosis strains to first-line anti-tuberculosis drugs [J]. Chinese Tuberculosis magazine, 2019, 41 (3): 364-368.
[13] Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: asystematic review by TB NET [J]. Eur Respir J, 2009, 33 (4): 871-881.
[14] Liu Binbin, Hu Peilei, Gong Daofang, et al. Drug resistance profile and influence of Mycobacterium tuberculosis in Hunan Province [J]. Chinese Journal of Infection Control, 2016, 15 (2): 73-78.
[15] Yuan Yanli, Yang Xiujun, Yang Guangxu, et al. Tuberculosis Drug Resistance Monitoring Study in Jilin Province [J]. Chinese Health Engineering, 2015, 2 (14): 70-72.
Cite This Article
  • APA Style

    Zhang Lifu, Zhang Wei Yu, Yang Xiujun, Liu Xin, Ma Yingcong, et al. (2022). Analysis of Drug Resistance of 157 Strains of Multidrug Resistant Mycobacterium Tuberculosis in Jilin Province. International Journal of Clinical and Experimental Medical Sciences, 8(5), 65-68. https://doi.org/10.11648/j.ijcems.20220805.11

    Copy | Download

    ACS Style

    Zhang Lifu; Zhang Wei Yu; Yang Xiujun; Liu Xin; Ma Yingcong, et al. Analysis of Drug Resistance of 157 Strains of Multidrug Resistant Mycobacterium Tuberculosis in Jilin Province. Int. J. Clin. Exp. Med. Sci. 2022, 8(5), 65-68. doi: 10.11648/j.ijcems.20220805.11

    Copy | Download

    AMA Style

    Zhang Lifu, Zhang Wei Yu, Yang Xiujun, Liu Xin, Ma Yingcong, et al. Analysis of Drug Resistance of 157 Strains of Multidrug Resistant Mycobacterium Tuberculosis in Jilin Province. Int J Clin Exp Med Sci. 2022;8(5):65-68. doi: 10.11648/j.ijcems.20220805.11

    Copy | Download

  • @article{10.11648/j.ijcems.20220805.11,
      author = {Zhang Lifu and Zhang Wei Yu and Yang Xiujun and Liu Xin and Ma Yingcong and Wang Hui},
      title = {Analysis of Drug Resistance of 157 Strains of Multidrug Resistant Mycobacterium Tuberculosis in Jilin Province},
      journal = {International Journal of Clinical and Experimental Medical Sciences},
      volume = {8},
      number = {5},
      pages = {65-68},
      doi = {10.11648/j.ijcems.20220805.11},
      url = {https://doi.org/10.11648/j.ijcems.20220805.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcems.20220805.11},
      abstract = {Objective: Through the analysis of drug resistance of 157 strains of multidrug resistant Mycobacterium tuberculosis in Jilin Province, the drug resistance spectrum of multi drug resistant Mycobacterium tuberculosis in Jilin Province was preliminarily established to provide the basis for the treatment of patients with multi drug resistant tuberculosis in the future. Methods: Anti-tuberculosis streptomycin (SM), ethambutol (EMB), of loxacin (OFX) and kanamycin (KM) were tested by L-J ratio. Results: The SM resistance rate in 157 MDR M. tuberculosis strains was 56.05%, EMB The resistance rate 38.85%, OFX The resistance rate 64.97%, KM The resistance rate 14.65%. The XDR resistance rate was 14.01%. The results of drug resistance analysis in different characteristic populations show that second-line drugs OFX and KM drug resistance rates Female patients Higher than male, and statistically significant (P < 0.05), the resistance rate of OFX relapse patients was significantly higher than that in naive patients, and was statistically significant (P < 0.05). Conclusion: The resistance rate of tuberculosis patients in Jilin Province to the first-line and second-line anti-tuberculosis drugs is at a relatively high level, and the situation of tuberculosis prevention and control is not optimistic. The management of patients should be strengthened in the prevention and treatment strategies, and the use of anti-tuberculosis drugs should be standardized, At the same time, strengthen the ability of tuberculosis laboratory to detect drug-resistant Mycobacterium tuberculosis is strengthened.},
     year = {2022}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Analysis of Drug Resistance of 157 Strains of Multidrug Resistant Mycobacterium Tuberculosis in Jilin Province
    AU  - Zhang Lifu
    AU  - Zhang Wei Yu
    AU  - Yang Xiujun
    AU  - Liu Xin
    AU  - Ma Yingcong
    AU  - Wang Hui
    Y1  - 2022/09/16
    PY  - 2022
    N1  - https://doi.org/10.11648/j.ijcems.20220805.11
    DO  - 10.11648/j.ijcems.20220805.11
    T2  - International Journal of Clinical and Experimental Medical Sciences
    JF  - International Journal of Clinical and Experimental Medical Sciences
    JO  - International Journal of Clinical and Experimental Medical Sciences
    SP  - 65
    EP  - 68
    PB  - Science Publishing Group
    SN  - 2469-8032
    UR  - https://doi.org/10.11648/j.ijcems.20220805.11
    AB  - Objective: Through the analysis of drug resistance of 157 strains of multidrug resistant Mycobacterium tuberculosis in Jilin Province, the drug resistance spectrum of multi drug resistant Mycobacterium tuberculosis in Jilin Province was preliminarily established to provide the basis for the treatment of patients with multi drug resistant tuberculosis in the future. Methods: Anti-tuberculosis streptomycin (SM), ethambutol (EMB), of loxacin (OFX) and kanamycin (KM) were tested by L-J ratio. Results: The SM resistance rate in 157 MDR M. tuberculosis strains was 56.05%, EMB The resistance rate 38.85%, OFX The resistance rate 64.97%, KM The resistance rate 14.65%. The XDR resistance rate was 14.01%. The results of drug resistance analysis in different characteristic populations show that second-line drugs OFX and KM drug resistance rates Female patients Higher than male, and statistically significant (P < 0.05), the resistance rate of OFX relapse patients was significantly higher than that in naive patients, and was statistically significant (P < 0.05). Conclusion: The resistance rate of tuberculosis patients in Jilin Province to the first-line and second-line anti-tuberculosis drugs is at a relatively high level, and the situation of tuberculosis prevention and control is not optimistic. The management of patients should be strengthened in the prevention and treatment strategies, and the use of anti-tuberculosis drugs should be standardized, At the same time, strengthen the ability of tuberculosis laboratory to detect drug-resistant Mycobacterium tuberculosis is strengthened.
    VL  - 8
    IS  - 5
    ER  - 

    Copy | Download

Author Information
  • Jilin Province Health Testing and Inspection Center, Changchun, China

  • Jilin Provincial Center for Disease Control and Prevention (Jilin Provincial Institute of Public Health), Changchun, China

  • Jilin Province Health Testing and Inspection Center, Changchun, China

  • Jilin Provincial Research Institute of Tuberculosis Prevention and Control (Affiliated Hospital), Changchun, China

  • Jilin Provincial Research Institute of Tuberculosis Prevention and Control (Affiliated Hospital), Changchun, China

  • Jilin Provincial Center for Disease Control and Prevention (Jilin Provincial Institute of Public Health), Changchun, China

  • Sections